Showing 1391-1400 of 1576 results for "".
- Topcon Healthcare Launches IDHea to Advance Digital Research in Eye Care and Oculomicshttps://modernod.com/news/topcon-healthcare-launches-idhea-to-advance-digital-research-in-eye-care-and-oculomics/2484202/Topcon Healthcare announced the launch of IDHea Inc., the Institute for Digital Health, a new company dedicated to transforming clinical research in eye care and the emerging field of oculomics—the study of ocular biomarkers that reflect systemic health.
- Virtual Vision Health Expands Virtual Eye Platform with New Diagnostic Modules and Multi-Exam Integrationhttps://modernod.com/news/virtual-vision-health-expands-virtual-eye-platform-with-new-diagnostic-modules-and-multi-exam-integration/2484191/Virtual Vision Health announced a series of upgrades to its Virtual Eye platform—a VR vision testing system designed to deliver immersive, data-driven visual field, progression analysis, and functional eye assessments.
- Konan Medical Receives CE Marking for ObjectiveFIELD Analyzer (OFA)https://modernod.com/news/konan-medical-receives-ce-marking-for-objectivefield-analyzer-ofa/2484170/Konan Medical USA announced that its objectiveFIELD Analyzer (OFA) has received CE Marking under the European Medical Device Regulation (MDR). The CE Mark enables Konan Medical to offer its next-generation perimetry solution to healthcare providers throug
- Oculus Smartfield Perimeter Launches Aboard the International Space Station to Support Vision Researchhttps://modernod.com/news/oculus-smartfield-perimeter-launches-aboard-the-international-space-station-to-support-vision-research/2484168/Oculus announced that its Smartfield perimeter has successfully launched aboard the International Space Station (ISS) to support research on Spaceflight Associated Neuro-ocular Syndrome (SANS)—a condition known to affect astronauts’ vision during l
- J&J to Present New Data Demonstrating Superiority of Acuvue Oasys Max 1-Day for Astigmatism at AAOpthttps://modernod.com/news/jj-to-present-new-data-demonstrating-superiority-of-acuvue-oasys-max-1-day-for-astigmatism-at-aaopt/2484158/Johnson & Johnson announced new clinical data demonstrating significantly higher end-of-day comfort and stronger overall patient preference for the Acuvue Oasys Max 1-Day for Astigmatism contact lenses compared to Dailies Total1 for Astigmatism.
- Regenxbio Completes Enrollment in ATMOSPHERE and ASCENT Trials of Sura-Vec Gene Therapy for Wet AMDhttps://modernod.com/news/regenxbio-completes-enrollment-in-atmosphere-and-ascent-trials-of-sura-vec-gene-therapy-for-wet-amd/2484155/Regenxbio announced the completion of enrollment in its two pivotal phase 3 studies—ATMOSPHERE and ASCENT—evaluating surabgene lomparvovec (sura-vec, ABBV-RGX-314), an investigational one-time gene therapy for wet age-related macular degeneration (
- SightGlass Vision: New 18-Month Data Reinforce DOT Lens Effectivenesshttps://modernod.com/news/sightglass-vision-new-18-month-data-reinforce-dot-lens-effectiveness/2484152/New 18-month clinical data presented by SightGlass Vision at the American Academy of Optometry 2025 annual meeting show that more than half of children wearing DOT spectacle lenses experienced no clinically meaningful myopia progression—nearly 4 times th
- Gen Z Contact Lens Adoption Presents Major Growth Opportunity, New CLI Research Showshttps://modernod.com/news/gen-z-contact-lens-adoption-presents-major-growth-opportunity-new-cli-research-shows/2484147/Fresh consumer data from the Contact Lens Institute (CLI) reveals that eye care professionals have a significant chance to boost contact lens prescribing among Gen Z patients. The findings—unveiled ahead of a main-stage session at Vision Expo West—h
- Visionix USA to Debut VX 40 Couture Auto Lensmeter at Vision Expo Westhttps://modernod.com/news/visionix-usa-to-debut-vx-40-couture-auto-lensmeter-at-vision-expo-west/2484141/Visionix USA will unveil its latest innovation—the VX 40 Couture—at Vision Expo West, September 18–21 at the Venetian Expo Center in Las Vegas. According to Visionix, the VX 40 Couture is a next-
- Formycon and Bio Usawa Partner Bio to Provide FYB201/ BioUcenta (Ranibizumab) Across Sub-Saharan Africahttps://modernod.com/news/formycon-and-bio-usawa-partner-bio-to-provide-fyb201-bioucenta-ranibizumab-across-sub-saharan-africa/2482870/Formycon announced a partnership between Bioeq AG—licensee and exclusive global commercialization rights holder for Formycon’s biosimilar FYB201—and African biotechnology company Bio Usawa Biotechnology. The agreement grants Bio Usawa exclusiv